CML Patients on Imatinib Live as Long as General Population

Posted by rob on April 1, 2011 under Uncategorized | Comments are off for this article

Patients with chronic myelogenous leukemia (CML) treated with imatinib who remain in complete cytogenetic remission for 2 years have survival rates comparable to the general population. Medscape Medical News (Source: Medscape Today Headlines)
More